Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03674814
Recruitment Status : Recruiting
First Posted : September 18, 2018
Last Update Posted : May 13, 2021
Sponsor:
Collaborators:
Corcept Therapeutics
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Chicago

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 10, 2023
Estimated Study Completion Date : March 10, 2025